STOCKHOLM, Jan. 7, 2024 /PRNewswire/ -- Calliditas
Therapeutics AB (Nasdaq: CALT) (Nasdaq Stockholm: CALTX)
("Calliditas") today announced that management will present at and
participate in the 42nd Annual J.P. Morgan Healthcare Conference,
which is taking place January 8-11,
2024, in San Francisco,
California. Calliditas will present an update on the company
at 7:30 am PT on Tuesday 9th
January.
For further information, please contact:
Åsa Hillsten, Head of IR & Sustainability, Calliditas
Tel.: +46 76 403 35 43, Email: asa.hillsten@calliditas.com
The information was sent for publication, through the agency
of the contact person set out above, on January 7, 2024 at 3:00
p.m. CET.
About Calliditas
Calliditas Therapeutics is a biopharma company headquartered in
Stockholm, Sweden, focused on
identifying, developing, and commercializing novel treatments in
orphan indications with significant unmet medical
needs. Calliditas' common shares are listed on Nasdaq
Stockholm (ticker: CALTX) and its American Depositary Shares are
listed on the Nasdaq Global Select Market (ticker: CALT). Visit
Calliditas.com for further information.
The following files are available for download:
|
https://mb.cision.com/Main/16574/3905093/2525028.pdf
|
JPM ENG
|
View original
content:https://www.prnewswire.co.uk/news-releases/calliditas-to-present-at-jp-morgan-healthcare-conference-302027785.html